Tags: Drug.

Remogliflozin etabonate (INN/USAN) is a proposed drug for the treatment of type 2 diabetes being investigated by GlaxoSmithKline. Remogliflozin is now being developed by BHV Pharma.[citation needed]

Remogliflozin_etabonate_structure.svg
ATC prefix
none
CAS number
442201-24-3
FDA UNII code
TR0QT6QSUL
IUPAC name
5-methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside

Loading...

This page contains content from the copyrighted Wikipedia article "Remogliflozin etabonate"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.